Long-term results of continuous treatment with recombinant interferon-α in patients with metastatic carcinoid tumors - An antiangiogenic effect?

Anti-Cancer Drugs

Volumn 7, Issue 2, 1996, Pages 175-181

  Dirix, Luc Y ^a,b   Vermeulen, Peter B ^a   Fierens, Herbert ^a   De Schepper, Bart ^b   Corthouts, Bob ^a   Van Oosterom, Allan T ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

angiogenesis; carcinoid tumors; interferon neuron specific enolase

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ACETYLSALICYLIC ACID; MARKER; NEURON SPECIFIC ENOLASE; PARACETAMOL; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD LEVEL; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; HUMAN; INTRON; LONG TERM CARE; MALE; METASTASIS; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; URINE LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON ALFA-2B; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029987910     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199602000-00005     Document Type: Article

References (32)

1. Goodwin DJ. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36: 560-9.
2. Moertel CG. Treatment of carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727-40.
3. Kvols LK. Metastatic carcinoid tumors and the carcinoid syndrome. Am J Med 1986; 81: 49-55
4. Öberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anti-Cancer Drugs 1994; 5: 503-19.
5. Thomas BM. Three unusual carcinoid turners, with particular reference to osteoblastic bone metastasis. Clin Radiol 1968; 19: 221-5.
6. Di Bartolomeo M, Bajetta E, Bochicchio AM, et al. A phase II trial of dacarbazine, fluorouracil, and epirubicin in patients with neuroendocrine tumors. A study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 1995; 6: 77-9.
7. Öberg K, Funa K, Aim G. Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and the carcinoid syndrome. N Engl J Med 1983; 309: 129-33.
8. Öberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leucocyte interferon: long-term results. Cancer Treat Rep 1986; 70: 1297-304.
9. Smith DB, Scarffe JH, Wagstaff J, Johnston RJ. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep 1988; 71: 1265-66.
10. Välimäki M, Järvinen H, Salmela P, Sane T, Sjöblom S-J, Pelkonen R. Is treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991; 67: 547-9.
11. Doberauer C, Mengelkoch B, Kloke O, Wandl U, Niederle N. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Acta Oncol 1991; 30: 603-5.
12. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leucocyte A interferon. J Clin Oncol 1989; 7: 865-8.
13. Noblin A, Lindblom A, Mansson B, Sundberg M. Interferon treatment in patients with malignant carcinoids. Acta Oncol 1989; 28: 445-9.
14. Veenhof CHN, de Wit R, Taal BG, et al. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumor. Eur J Cancer 1992; 28: 75-8.
15. Biesma B, Willemse PHB, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas, effect on tumours and tumour makers. Br J Cancer 1992; 66: 880-5.
16. Hanssen LE, Schrumpf E, Jacobsen MB, et al. Extended experience with recombinant α2b interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumors. Acta Oncol 1991; 30: 523-27.
17. Åberg K, Nordheim I, Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of stretozotocin plus 5-FU and human leucocyte interferon. Eur J Cancer Clin Oncol 1989; 25: 1475-9.
18. Tiensuu Janson E, Rönnblom L, Ahlström H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992; 3: 635-638.
19. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641-7.
20. Fabris P, Betterle C, Florerani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340: 548.
21. Stewart TA, Hultgren B, Huang X, et al. Induction of type 1 diabetes by Interferon-α in transgenic mice. Science 1993; 260: 1942-6.
22. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155-61.
23. Öberg K. The action of interferon alpha on human carcinoid tumours. Sem Cancer Biol 1992; 3: 35-41.
24. Lengyel P. Tumor-suppressor genes; news about the interferon connection. Proc Natl Acad Sci USA 1993; 90: 5893-5.
25. Gutterman JU. Cytokine therapeutics: lessons from interferon α Proc Natl Acad Sci USA 1994; 91: 1198-205.
26. Fujimoto K, Ichimori Y, Kakizoe T, et al. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commum 1992; 180: 386-92.
27. Nanus DM, Schmitz-Dräger BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993, 85: 1597-9.
28. Bordi C, Falchetti A, Buffa R, et al. Production of basic fibroblast growth factor by gastric carcinoid tumors and their putative eels of origin. Hum Pathol 1994; 25: 185-80.
29. Beauchamp RD, Coffey RJ, Lyons RM, et al. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cel growth. Cancer Res 1991; 51: 5253-60.
30. Takahashi K, Mulliken JB, Kozakewich HPW, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357-64.
31. Munck J-N, Cvitkovic E, Piekarski J-D, et al. Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer. J Natl Cancer Inst 1991; 83: 569-75.
32. Andersson T, Wilander E, Eriksson B, et al. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res 1990; 50: 3413-5.